Escitalopram/reboxetine combination in depressed patients with substance use disorder.
Acting pharmacologically on different transmitter systems has been suggested to have some advantages in patients with substance abuse and may possibly address a larger spectrum of symptoms. One major drawback of using antidepressants addressing several neurotransmitters is that the relative activities on the different neurotransmitters cannot individually be adjusted. Combining antidepressants targeting different neurotransmitter systems may allow adapting the effect on each neurotransmitter system corresponding to patients' response and tolerance. Three cases of patients presenting a substance use disorder with comorbid major depression episodes are presented, who were treated with a reboxetine/escitalopram combination and who showed a rapid response of their depressive syndrome.
Camarasa
Xavier
X
Hôpital Psychiatrique Cantonal de Marsens, Switzerland.
Lopez-Martinez
Elena
E
Duboc
Annik
A
Khazaal
Yasser
Y
Zullino
Daniele Fabio
DF
D000328:Adult; D000437:Alcoholism / Q000150:complications / Q000534:rehabilitation; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000150:complications / Q000188:drug therapy; D015283:Citalopram / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000150:complications* / Q000188:drug therapy*; D017831:Diagnosis, Dual (Psychiatry); D004338:Drug Combinations; D005260:Female; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D000077593:Reboxetine; D019966:Substance-Related Disorders / Q000150:complications* / Q000188:drug therapy*
D000928:Antidepressive Agents; D004338:Drug Combinations; D009025:Morpholines; D015283:Citalopram; D000077593:Reboxetine